Shares of Cencora (COR) lost 3.9% on Jun 27, followed by another 1.3% decline during the after-hours trading. This was likely due to the invalidation of a previously-settled opioid litigation by the Supreme Court. Meanwhile, an assumed softness in the retail pharmacy market is likely to have added to the pressure. However, Cencora has the ability to turn around with a multinational distribution footprint and a global platform of commercialization services that make it a natural partner for manufacturers bri ...